However, he is hopeful the ONJ Institute can push the findings towards clinical trials in the future, saying the study has ‘strong rationale’ to continue development.
‘Because we work in the same building as our oncologist colleagues at Austin Health, our discoveries in the laboratory can be quickly translated into patient trials,’ he said.
Professor Ernst’s research shows inhibition of haematopoietic cell kinase (HCK), a protein found in a type of immune cell, improves the response of pancreatic cancer to immunotherapy in preclinical models.
The drug has also been theoretically proven to limit the process of metastasis, reducing the spread of cancer cells to other areas of the body.
Another member of the research team, Postdoctoral Research Fellow co-lead Dr Ashleigh Poh from the ONJ Institute, said this could mean big things for pancreatic cancer treatment because most patients suffering from it don’t respond to existing anti-cancer drugs.
‘The survival rate of pancreatic cancer has not improved over the past few decades,’ Dr Poh said.
‘We hope to eventually translate these findings into the clinic and improve survival outcomes for pancreatic cancer patients.’
The pancreas is an organ that sits behind the lower part of the stomach and aids in digestion and metabolising sugars.
Pancreatic cancer is almost completely unresponsive to current immunotherapy, which reactivates the immune system so it can recognise and remove cancer cells.
It does not present symptoms during the early stages and spreads rapidly throughout the body, with other treatments involving surgically removing the pancreas, radiation or chemotherapy.
Approximately 4,260 new cases are diagnosed every year in Australia, with the survival rate as low as 11 per cent five years after diagnosis.
Post courtesy of The Daily Mail
